Ebunat 0.5mg Injection contains Eribulin Mesylate (0.5 mg), which is a microtubule dynamics inhibitor used primarily for the treatment of certain cancers, such as metastatic breast cancer and liposarcoma. Derived from a naturally occurring marine sponge product, eribulin inhibits the division of cancer cells by interfering with microtubule function.

Brand Name: Ebunat

Composition: Eribulin Mesylate

Mechanism of Action:

Eribulin prevents cancer cells from dividing and ultimately causing cell death by blocking the growth phase of microtubules, which are vital parts of the cellular skeleton.

Uses:

• Metastatic Breast Cancer
• Metastatic Liposarcoma

Dosage and Administration:

Intravenous injection (IV) is the method of administration. Body surface area (BSA) is typically used to calculate dosage.

Side Effects:

• Fatigue
• Nausea
• Constipation
• Hair loss
• Weakness
• Numbness or tingling in hands and feet
• Fever
• Anemia
• Decreased appetite

Safety Advise:

Liver  

Dosage modifications may be necessary for patients with hepatic impairment. Testing for liver function should be done on a regular basis. Kindly speak with your healthcare provider.

Kidney  

Dosage modifications may be necessary for patients with renal impairment. Testing for kidney function should be done on a regular basis. Kindly speak with your healthcare provider.

Pregnancy  

Eribulin should not be used during pregnancy since it may harm the fetus. Kindly speak with your healthcare provider.

Breast Feeding  

Eribulin may harm the baby if it gets into the breast milk, hence it is not recommended during treatment. Kindly speak with your healthcare provider.

Alcohol  

The safety of consuming alcohol while using Ebunat 0.5mg Injection is unknown. Kindly speak with your healthcare provider.

Storage:

Store vials at 2°C to 8°C (36°F to 46°F) in a refrigerator. Do not freeze.

How to use this Medication?

Eribulin injection is administered intravenously (into a vein) by a physician or nurse at a hospital, infusion facility, or doctor's office as a solution (liquid) over a period of two to five minutes. In a 21-day cycle, it is typically administered on days 1 and 8.

If you have certain adverse effects, your doctor might need to reduce your dosage or postpone your treatment. Throughout your treatment, be sure to communicate your feelings to your doctor.

References:

1.      Malleswari PN, Gupta PV, Vardhan SV, Ramachandran D. Quantitative estimation of ethanol content in eribulin mesylate injection using headspace gas chromatographic with flame ionization detector [HS-GC-FID]. The Scientific Temper. 2024 Jun 15;15(02):2039-44.

2.      Huyck TK, Gradishar W, Manuguid F, Kirkpatrick P. Eribulin mesylate. Nature reviews drug discovery. 2011 Mar 1;10(3):173.

3.     Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clinical Cancer Research. 2015 Jun 1;21(11):2445-52.

4.      Cigler T, Vahdat LT. Eribulin mesylate for the treatment of breast cancer. Expert opinion on pharmacotherapy. 2010 Jun 1;11(9):1587-93.

5.    Aseyev O, Ribeiro JM, Cardoso F. Review on the clinical use of eribulin mesylate for the treatment of breast cancer. Expert Opinion on Pharmacotherapy. 2016 Mar 3;17(4):589-600.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Natco Pharma Ltd

Address: Natco House, Road No.2, Banjara Hills, Hyderabad-500 034, India

Country of origin: India